ARS Pharmaceuticals (SPRY) Accounts Payables (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Accounts Payables data on file, last reported at $48.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 78.69% year-over-year to $48.3 million; the trailing twelve-month figure through Mar 2026 stood at $48.3 million (up 78.69% YoY), and the FY2025 full-year result was $37.9 million, up 66.14% from the prior year.
• Accounts Payables improved to $48.3 million in Q1 2026, from $37.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $49.8 million in Q3 2025 to a low of $126000.0 in Q3 2022.
• A 5-year average of $17.6 million and a median of $9.8 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables slumped 92.67% in 2022 and soared 8586.51% in 2023, its largest moves.
• Tracing SPRY's Accounts Payables over 5 years: stood at $4.9 million in 2022, then tumbled by 56.32% to $2.2 million in 2023, then jumped by 960.4% to $22.8 million in 2024, then jumped by 66.14% to $37.9 million in 2025, then grew by 27.18% to $48.3 million in 2026.
• Business Quant data shows SPRY's Accounts Payables at $48.3 million in Q1 2026, $37.9 million in Q4 2025, and $49.8 million in Q3 2025.